Replies to post #181 on ArQule Inc. (ARQL)

[surf1944]

8:07AM ArQule announces commencement of Phase 3 clinical trial with Tivantinib in Hepatocellular Carcinoma by partner Kyowa Hakko Kirin in Japan (ARQL) : Co reports the announcement by its partner, Kyowa Hakko Kirin Co., of the initiation of a Phase 3 clinical trial evaluating tivantinib in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy. The trial is a randomized, double-blind placebo-controlled study to compare progression-free survival in patients treated with tivantinib with those treated with placebo. Kyowa Hakko Kirin plans to enroll approximately 160 patients in this study.